AMRX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Amneal Pharmaceuticals, Inc. Class A Common Stock · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 18.32 USD
2.2% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 28.9% above the Trend Line and sits at 91.8% of its 52-week range. The latest completed week returned 2.2%, after a 6.8% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. Options positioning is volatility with 46/100 conviction, while the latest news-sentiment score is 59/100. Near-term considerations: price is close to its 52-week high; earnings are due in 1d.

Setup score 72 out of 100
Latest Close 18.32 USD 31 Jul 2026
1W Return 2.2% latest completed week
4W Return 6.8% short-term follow-through
12W Return 38.8% quarterly tape
Trend Breadth 90.4% 47 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • The trend backdrop is active with a 8-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 2 reversal markers appear in the recent smart-money tape.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 2.2% Latest completed week; four-week move 6.8%. Indicator stack 77/68 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 57.42% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 46/100 conviction; expected move 10.6%. News sentiment 59/100 67 relevant articles in the latest sentiment read. Event risk 1d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 28.9% above the Trend Line and sits at 91.8% of its 52-week range. The latest completed week returned 2.2%, after a 6.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8512-week average 0.55

12-week confirmation

Trend active8/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership9/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.85Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 6.8% over four weeks, 38.8% over 12 weeks, and 134.0% over one year. The current trend has remained active for 8 consecutive weeks.

Performance by holding period

1W2.2%
4W6.8%
12W38.8%
26W33.9%
52W134.0%
Active trend streak8 weeks
Active weeks in one year47
Trend breadth90.4%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.08Latest activity-pressure read.
Pressure change-19.1%Four-week change in activity pressure.
Leadership32.23Latest relative-leadership reading.
RS change30.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 30 Jun 2026 Field coverage 94% Model confidence 94%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength59/100Blend of value, momentum, and quality. Underlying universe rank 42; rank 1 is best.
Value17/100Relative valuation strength. Underlying universe rank 84; rank 1 is best.
Quality83/100Profitability and accounting quality. Underlying universe rank 18; rank 1 is best.
Momentum97/100Medium-term price momentum. Underlying universe rank 4; rank 1 is best.
Growth24/100Revenue and earnings growth. Underlying universe rank 77; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework48/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
37.1x
Price divided by trailing earnings.
Price / sales
1.9x
Market value relative to trailing revenue.
EV / EBITDA
13.2x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
3.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
39.3%
Gross profit retained from each unit of revenue.
Operating margin
14.4%
Operating profit retained from revenue.
Free-cash-flow margin
10.2%
Free cash flow generated from revenue.
Return on invested capital
12.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
9.3%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-27.6%
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.0%
Net share repurchases relative to market value.
Shareholder yield
-0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
4.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

AMRX shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 1.62, expected move of 10.6%, and Sharemaestro trend signal active.

Conviction46/100
Expected move10.6%
Put/call volume1.63
Pressure-18
Speculation42
Volatility96
Trend agreement77
Open options detail
Insider activity11 / 9

11 acquisitions and 9 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment59/100

Weighted news tone is neutral across 67 relevant articles.

30 positive · 33 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings1dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move10.6%Nearest-chain priced movement where available.
52-week drawdown-4.9%Distance below the 52-week high.
13-week volatility5.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher17 of 268 weeks finished lower.
Best week+17.8%Week of 12 Jun.
Worst week-10.6%Week of 13 Mar.
Latest week+2.2%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains8
Flat weeks1
Modest losses3
Sharp losses5
Recent vol5.9%13-week weekly-return volatility.
Base vol5.0%52-week weekly-return volatility.
Up/down split35/16Count of positive and negative weeks in the 52-week window.
Average skew4.2% / -3.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape70/100

Trend, activity pressure, participation, and risk combine to a 70/100 tape read.

 Indicator analysis63/100

Latest 12-week confirmation: trend 8/12, activity pressure 7/12, relative leadership 9/12.

Activity pressure 0.85; 2 reversal markers Next-Week ExpectancyPositive 57.42%

Next-week expectancy is positive with a 57.42% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors63/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 70; Small Cap Core rank 93 SVQF48/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 380.0 of 725 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options56/100

AMRX shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 1.62, expected move of 10.6%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 10.6% Sentiment59/100

Weighted news tone is neutral across 67 relevant articles.

Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance Insiders11 / 9

11 acquisitions and 9 disposals in the latest 180-day insider tape.

 Earnings1d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202618.32 USD2.2%14.22 USD8.78 USD1.0832.239.4MOn
24 Jul 202617.92 USD0.4%14.03 USD8.69 USD1.0731.628.3MOn
17 Jul 202617.85 USD4.9%13.86 USD8.59 USD1.2430.5110.9MOn
10 Jul 202617.01 USD-0.8%13.69 USD8.50 USD1.2320.548.5MOn
3 Jul 202617.15 USD-0.5%13.53 USD8.41 USD1.3424.778.0MOn
26 Jun 202617.23 USD6.3%13.36 USD8.32 USD1.0627.5616.4MOn
19 Jun 202616.21 USD0.1%13.20 USD8.23 USD0.5215.718.6MOn
12 Jun 202616.20 USD17.8%13.06 USD8.14 USD-0.0719.5812.7MOn
5 Jun 202613.75 USD4.4%12.91 USD8.06 USD-0.714.677.7MOff
29 May 202613.17 USD6.0%12.83 USD7.99 USD-0.89-3.767.9MOff
22 May 202612.42 USD4.1%12.75 USD7.92 USD-0.96-6.266.8MOff
15 May 202611.93 USD-9.6%12.69 USD7.85 USD-0.90-8.567.6MOff
8 May 202613.20 USD2.9%12.62 USD7.79 USD-0.721.087.5MOn
1 May 202612.83 USD2.5%12.51 USD7.72 USD-0.794.028.1MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.